1. Rediscovery of NF‐κB signaling in nasopharyngeal carcinoma: How genetic defects of NF‐κB pathway interplay with EBV in driving oncogenesis?
    Mei Yi et al, 2018, Journal of Cellular Physiology CrossRef
  2. Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
    Youwen Zhu et al, 2022, Frontiers in Pharmacology CrossRef
  3. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
    Zi-Lu Huang et al, 2019, Cancer Cell International CrossRef
  4. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
    Shin Hye Yoo et al, 2019, Scientific Reports CrossRef
  5. The Prognostic Role of Programmed Death‐Ligand 1 in Nasopharyngeal Carcinoma
    Michael Wotman et al, 2020, The Laryngoscope CrossRef
  6. Analysis of Epstein–Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region
    Josiane M. Dias et al, 2022, International Journal of Molecular Sciences CrossRef
  7. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect
    Pui Yan Siak et al, 2023, Journal of Translational Medicine CrossRef
  8. Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma
    David Johnson et al, 2021, Oral Oncology CrossRef
  9. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma
    Mona M. Ahmed et al, 2021, Applied Immunohistochemistry & Molecular Morphology CrossRef
  10. A Clinical-Radiomics Nomogram Based on Computed Tomography for Predicting Risk of Local Recurrence After Radiotherapy in Nasopharyngeal Carcinoma
    Chaohua Zhu et al, 2021, Frontiers in Oncology CrossRef
  11. Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer
    Fengge Zhou et al, 2022, Frontiers in Immunology CrossRef
  12. Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
    Yi-Qun Jia et al, 2019, Aging CrossRef
  13. Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Siqing Jiang et al, 2022, Frontiers in Immunology CrossRef
  14. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma
    Ju Zhao et al, 2022, Scientific Reports CrossRef
  15. Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma
    Yuan Qu et al, 2018, Molecular and Clinical Oncology CrossRef
  16. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients
    Xiaofeng Liu et al, 2019, Frontiers in Oncology CrossRef
  17. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
    Yabing Cao et al, 2019, BMC Cancer CrossRef
  18. Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy
    Yu-Jen Liu et al, 2018, Cancers CrossRef
  19. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma
    Noppadol Larbcharoensub et al, 2018, American Journal of Clinical Oncology CrossRef
  20. The Three P’s: Parotid, PD-L1, and Pembrolizumab
    Amanda Wiggins et al, 2019, Case Reports in Oncological Medicine CrossRef
  21. The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma
    ChangYin Feng et al, 2021, Applied Immunohistochemistry & Molecular Morphology CrossRef
  22. Cancer Immunotherapy for Nasopharyngeal Carcinoma
    Dora L.W. Kwong et al, 2019, Nasopharyngeal Carcinoma CrossRef